Cas:781588-93-0 Methyl (2R)-2-piperazinecarboxylate manufacturer & supplier

Chemical Name:Methyl (2R)-2-piperazinecarboxylate

CAS.NO:781588-93-0

Synonyms:Methyl (2R)-2-piperazinecarboxylate

Molecular Formula:C₆H₁₂N₂O₂

Molecular Weight:144.17200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:50.36000

Exact Mass:144.09000

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Methyl (2R)-2-piperazinecarboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Methyl (2R)-2-piperazinecarboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methyl (2R)-2-piperazinecarboxylate Use and application,Methyl (2R)-2-piperazinecarboxylate technical grade,usp/ep/jp grade.

Related News: The UK government has set out plans to make the UK the best destination in the world for researchers, making sure that it continues to attract the brightest and best from the UK and from overseas, cementing its status as a science superpower. 1-Pyrrolidinecarboxylic acid,4-[4-amino-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-(hydroxymethyl)-, 1,1-dimethylethyl ester, (2R-cis)- manufacturers RELATED: With cost cuts and asset sales largely wrapped, Takeda gears up for growth: CEO 1H-Benzimidazole, 2-ethyl-5-methoxy-1-(3-methoxyphenyl)- suppliers During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031. 1,2,3-benzotriazol-1-yl 2-triphenylmethylamino-1,3-thiazole-4-carboxylate vendor & factory During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031.,RELATED: With cost cuts and asset sales largely wrapped, Takeda gears up for growth: CEO